had growth the second Joe. decreased you, X.X%. second points. sales growth, In currency increased currency, declined the decrease our quarter of excludes a effect of U.S. X.X% a sales for $XX.X translational of U.S. X.X negative outside reported Thank of versus Worldwide X.X%. the were which XXXX. quarter billion impact as In by regions the XXXX, X.X% of the Operational sales
X.X% outside growth impacting X.X currency reported by Operational sales U.S. the with results OUS negatively was our points.
worldwide, growth X.X% the divestitures, and and impact U.S. Excluding outside adjusted the U.S. sales net X.X% of the operational flat in was acquisitions
to now earnings. Turning
was $X.X a earnings diluted $X.XX diluted $X.XX versus share billion per were of the net earnings earnings ago. quarter per and For year share
second operational expense diluted for quarter the grew for to the share per Excluding On XX.X%. adjusted the $X.XX, XX.X% billion and was XX.X%, of respectively, representing XXXX. diluted earnings adjusted share asset quarter of periods, an earnings and after-tax amortization intangible net adjusted earnings were both items and increases compared $X special per basis,
with slides front in comment now represent I change quarter translation. business of performance build impact of otherwise operational highlighting for the you. on comparison currency Unless the will quoted have quarter segment the sales exclude second you XXXX, of the second Beginning stated, upon in and sales percentages items that therefore, Consumer, to the
Worldwide sales totaled X.X%. billion Consumer $X.X segment growing at
the in with Excluding our share operational Consumer or U.S. in beauty X.X%, the of of primarily growth net was regions. impact of and continues franchise. to in divestitures. The ROC adjusted across exclude the category acquisitions X.X% growth double-digit all channel the strong X% the to Growth impact divestitures, sales was acquisition grow rates the that CI:LABO growth in due X.X%. and to and adjusted strong e-commerce grew performance strong XX.X% with outside DR. its U.S. the beauty channel. Outpacing about growth NIZORAL franchise of
channels with priority growth our e-commerce Our NEUTROGENA brands facial AVEENO Share sales NEUTROGENA categories. club treatment protection the to and due the growth and and sun combined moisturizing strong strong in was in share in U.S. delivered performance in results realized
AVEENO aided new MOISTURE products brands OGX hair by further from growth, the expansions. experience market stocking for retail continued solid was resulting launch, to really and MAUI
just the share. X% globally, acquisition, to U.S., which grew or ZARBEE's was over growing medicines exclude In to and sales of impact growth X.X% well. perform OTC continues adjusted is the adjusted operational when X% Over-the-counter
core However, grew by market sales the impacted a negatively U.S. share. contributor ZYRTEC of and retail growth was inventory factors. was
and growth. significant gel, TYLENOL well TYLENOL the to continues and strong share MOTRIN children's in realizing pediatric products. analgesics growth delivered share Adult outpacing also TYLENOL by sales arthritis category, consumption growth and release with Additionally, driven drive consumption double-digit rapid
with and its stocking consumption as quarter, this sell-through occurred slightly seasonal response of declined Maria in retail Hurricane lapping levels retailer of the by was elevated disruption sales associated TYLENOL dynamics. supply XXXX to However, inventory than the offset other and more that the
The grew performance relaunch to Baby Johnson's it markets all lapping Care segment, was destocking X.X% Consumer been Johnson's retail Growth other the due the events relaunch on is stabilizing in relaunched. where Baby associated globally. in has Concluding and with primarily U.S.
by worth growth XXX on basis worldwide enabled impacted were in nine Moving respectively. double-digit DARZALEX. XXX and U.S. U.S. by by billion Generic about our by growth outside products. XXX XX.X%. worldwide, the Pharmaceutical outside by the basis U.S. Pharmaceutical $XX.X pricing key almost sales to in favorable driven X.X% U.S. Worldwide points grew points one-time Sales points and adjustments primarily aided our segment. X% competition the negatively ZYTIGA basis Sales and by declined increased for of
and capabilities enabled and generic products commercial deliver at us competitive has of portfolio growth significant strong despite to global headwinds. Our biosimilar levels
about Our penetration well continued all the of market globally, XX% lines double-digit point as as of Of share continued for U.S. about strong the is regulatory the subcutaneous the the strong reimbursement growth to completion countries. and by increase where market formulation continues related European U.S. XX% The U.S. and favorable outside oncology adjustment across certain increased countries gains Pacific The U.S. multiple we XX% XX growing the discussions last myeloma when X about with in and of commercially just a EMEA it is note, and therapeutic or worldwide DARZALEX share quarter across to area America Asia of in benefit therapy. from strong submission grew Latin a of available, in region. growth, and delivered filed a pricing another week, for removing driven impact its performance the XX.X%. one-time growth strong DARZALEX
about outside growth of in new first approximately across and globally share declines IMBRUVICA Worldwide points be market U.S. the share, of share U.S. on gained X which grew lymphocytic patient in across almost market the and indications and and In European by by competition, share ZYTIGA in the line Asia generic which XX% to XX% the and of leukemia, XX% indications IMBRUVICA of uptake gains over U.S. data with the therapy. driven lines market declined in along and one driven was growth by continues Pacific offset quarter growth gained points by based strong U.S. about U.S., chronic patient largely the strong markets. X partially of all total of with outside therapy, XX% market the leader multiple
pleased we and of the indication continue were be and to penetration prescribers with risk share almost the of in in among evenly cancer, cancer, X based the castration-sensitive sales U.S., by driven with market on prostate and gains urology points launch prostate progress which Europe metastatic practices. oncology ERLEADA, market growth non-metastatic clinical high Strong castration-resistant share from trial. the LATITUDE primarily growth split Asia of gained In expanded in
also with available are is in progress where launch countries. in the five pleased EMEA, ERLEADA now We early
and filed of in quarter the Europe regulatory are pleased of for early with adults During U.S. treatment progress metastatic cancer. cancer. BALVERSA for with launch we the prostate locally castration-sensitive or advanced metastatic submissions urothelial we the Further, the
pleased very by quarter portfolio from of in driven remain under the of with the the increased strong global Crohn's performance share with points XX%, Our where disease U.S. STELARA uptake of by market X% continued in the compared primarily immunology disease X XXXX. delivered in of STELARA indication. to second sales has Crohn's just growth growth We over
by continued share growth and partially mechanisms increased biosimilars. erosion Sales of of loss to XX% is REMICADE modest offset U.S. in action the and due discounts, alternative of to
totaled is points $XXX in million over the TREMFYA demand patients share market achieved psoriasis XX,XXX quarter TREMFYA up and X a second the Lastly, U.S., globally, therapy. on strong from experiencing the of XXXX. with X.X% is which
diseases, portfolio for market of by grew products. increased JULUCA other offset strong HIV SYMTUZA X.X% led infectious In growth competition cannibalization our in and and by partially
long-acting paliperidone increased new with persistency. about higher In growing starts and strong well, driven market by neuroscience, our patient share, XX% portfolio performed
resistant the launch with depression. daily. sites are with In SPRAVATO program treatment performances pleased treatment and There centers are new REMS addition, X,XXX certified more added for being are the than we
and primarily In competition PROCRIT. by XARELTO continues XX.X% of declining our biosimilar other we in cardiovascular, experience TRx to for portfolio, increase INVOKANA share. metabolism driven XARELTO, declines product did sales and
legislative resulting the utilization was donut in uptake XX%, along share in overall XX% and the with in from the the However, higher rate XX% decline an increase donut hole XARELTO offset of Medicare by to for quarter. this hole
in milligram this expect the a We've value of expanded patients. recur to new response this population PAD are indication. we the to indication we XARELTO's seen over provides patient while time, dose for and X.X vascular positive confident to penetration And the CAD
benefited competition by in pulmonary market and performance X% from by XX% partially strong total and further by This U.S. in growth increased U.S. the generic as impacted which growing grew OPSUMIT and with XX% Both UPTRAVI on well by portfolio entry about generic recent share. continued the respectively a penetration negatively basis. is was TRACLEER hypertension Our of both as global the outside offset
Medical I'll turn Devices now the sales to billion, declining your were segment. Medical Worldwide attention X.X%. $X.X Devices
growth and operational Excluding was X.X% sales the divestiture acquisitions and primarily adjusted worldwide. net impact divestitures, the of of LifeScan ASP,
supply challenges Medical XXX with representative isolated for delivered we being progress this, worldwide. over first segment. X% Devices in have the consistent growth As points have did performance just improve would made in impacted about quarter continued Joe of and quarter by mentioned, growth a some of Adjusting the that the this negatively basis to
Solutions globally, offerings double-digit XX% to strength growth. Interventional product in in market by advanced than about all electrophysiology catheters continued continuing our our growth worldwide led procedural business XX% contributing more trend and in regions, strong growth. grew of atrial driven Growth ablation by newer was fibrillation achieving its
Additionally, a fourth the by innovation, driven double-digit stroke as of as the business we product delivered treatment growth. ischemic quarter in of growth strong straight for well including market new EmboTrap CERENOVUS
contact daily astigmatism X.X% lenses led disposables driven in OASYS and was the Vision grew by of by lenses growth globally which X% almost family.
U.S. of consistent the and of with X.X% XXXX when year-to-date with strong divestitures contact growth just of and both QX under versus adjusting acquisitions, Orthopedics days. business Our selling X% in X.X% remained or for OUS. remained growth lenses growth
to growth to our We continue remain in innovation improve this executing and to to make that progress improve aim performance. we commercial franchise plans committed and
which primary selling stem leadership in position we the represent anterior to which is the demand number X.X%, by our globally, performance grew continued U.S. and ACTIS, driven above strong now expect for our market approach our stem in Hips
in replace hip Surgical KINCISE handheld is procedures our designed the the enabling Additionally, to Impactor U.S. mallet
is the was half. driven growth market quarter. adoption consecutive and second and of timing the point to Nails. supported Growth X market of tender was accelerated X.X% of with Femoral for U.S. as outside shifting The innovation in due the newer such be Trauma our flat adjusting of selling also by line globally when impacted was U.S. strong growth by days over X.X% to Recon third rate by a the for growth to expected
being the the with U.S. driver of decline. declined Spine over the X% primary
products acquisitions, and VIPER U.S. performance pedicle all-in-one a for by we minimally days was System PRIME and driven selling to growth for such Our system for adjusting EXPEDIUM flat while our continue new screw see of divestitures stabilization when deformity. some surgery invasive as VERSE
opportunities complex such in We innovations cervical. launch to we the improve growth in pursue half as Symfony continue second to further system new plan to the including
System quarter above including innovation, Knees is by with positive declined of U.S. strong including being less addressing by The than but from continue the performance Offsetting S+. the X% expected gaps driver led U.S., is it and uptake Cementless ATTUNE of year. expected X% have we the growth portfolio to the launch U.S. decline. commercial the Revision in over market represent we to market of realizing the Revision offering later which the new outside are this our performance, to full enhance ATTUNE
in all overall impact relatively stable compared to continued pressure categories Pricing QX. but orthopedics to was
across For price price all knees X% and the X%. pure hips, was pure U.S. negative down declined quarter platforms. price approximately Spine about with trauma all
in primarily products both driven by the for performance the strong gains X% over new the by surgery of and in business. region. energy and Asia-Pacific results to share delivered Surgery Turning just global led growth Advanced endocutters
due declined which to SURGIFLO Biosurgery biosurgery in impacted U.S. of stopped points. X% over shipment by a growth by global XX the
We FDA work will ensure important available the market to to as patients the soon this in technology continue is for as U.S. again possible. with
due points will XXX negatively surgery grew closure and in actions in share. the was distributing Across customers June. Corrective action on and impacted by began barbed sutures Staplers. field taken growth to basis X% conventional general Intraluminal Wound worldwide to quarter our as total we gained were approximately a
any in second growth impact a on Selling days subsequent in we expect XXXX. global not impact the quarter, quarter a and negative in minor do had rates significant our
from feedback comment received we Medical community. analyst the There’s based Devices on on final a
will These trends the on compete. limited our be this in utilization external providing actual data to based were correlation during no longer We provide estimates low segments call. and a we performance market
surgical For procedures approximately increased quarter. X.X%, Hospital the for X% X.X%, lab did latest to last QX utilization, want and provide we final and estimates the by shared update admissions, on you respectively. we since figures procedures all
provide for our now will the some I commentary earnings on quarter.
please attention earnings statement the of quarter your consolidated the second our boxed XXXX to Regarding the schedule. of direct for of section
As the adjusted to $X intangible on table basis, by measures, and quarter billion. referenced special billion the expense earnings asset an primarily second after-tax amortization net amortization non-GAAP XXXX of in intangible items of are exclude driven of $X.X
XXXX. impact items, $X.XX, of quarter on versus second Excluding $X.XX, up basis currency versus per our those the adjusted share earnings is the XXXX. of XX.X% second constant was an XX.X% EPS a quarter increase Adjusted
like few of Consumer I'd by which improvement in selling, and a slightly to was of that driven sold delevered by administrative our product marketing now Pharmaceutical the for same result the quarter last quarter on business. of noteworthy earnings, margins highlight primarily offset in leverage have Cost items a to year. products the as compared and mix, changed statement
R&D ASP We and quarter Devices our to gain as than our higher by This which higher driven points. by XX%, including other increased our continue digital of second investment research and The was business competitive the by in to primarily is development robotics. increase levels a quarter expense invest and levels line income recorded the sales driven income platforms, at was in primarily the divestiture. in XX on investment in Medical XXXX percent basis development the of was of surgery support this the
by cross lower hedging investment Net million, the arrangements interest primarily expense $XXX swaps. positive by certain and effect was currency driven net of
encourage our specific in was further in XXXX Regarding effective with on tax our XX.X%. for the quarter of XX.X% details second of you matters. reference We XX-Q tax taxes line quarter, the rate to
items, same effective compared last XX.X% XX.X%, to rate tax special was the year. period Excluding the in
the of gain the ASP on impact tax the includes XXXX divestiture. of quarter second The
our primarily in tax for driven the divestiture enterprise ASP. In on gain quarter Now income before the looking XX.X% increased by to of tax. adjusted at XXXX, before the from XX.X% XXXX, second income the of adjusted
are adjusted main following drivers by The income the before tax of segment:
XXX by decrease Medical also partially due surgery. other Consumer in XXXX, margins and from to because Devices margins offset of mix digital XX.X% selling expenses. marketing decreased points basis Pharmaceutical lower the by in leveraging in by gain increased product partially was income. divestiture XX.X% lower driven by offset gains were investments to in and on The that the ASP basis points, divestiture by primarily XXX
and That quarter P&L Johnson’s for sales XXXX. concludes Johnson second the & highlights
your For summarizing occurring a reference, in quarter. notable the here's slide developments second
in my mentioned of were Some comments. which
to call I will back turn the Joe.
